repository
섬유성 망막 질환에서 전이성장인자 신호전달과정 억제를 통한 항섬유화 약물 (pirfenidone)의 효과 및 기전
- Alternative Title
- Effect of Anti-fibrotic Drug (Pirfenidone) on TGF-β Signaling Pathway in Ocular Fibrotic Disorders
- Author(s)
- 이기황
- Alternative Author(s)
- Kihwang Lee
- Advisor
- 안재홍
- Department
- 일반대학원 의학과
- Publisher
- The Graduate School, Ajou University
- Publication Year
- 2015-08
- Language
- eng
- Keyword
- Transforming growth factor-β (TGF-β); retinal pigment epithelial (RPE) cells; fibrosis; pirfenidone; cell singnal; epithelial-mesenchymal transition
- Alternative Abstract
- Purpose: Transforming growth factor-β (TGF-β) plays a key role in transforming retinal pigment epithelial (RPE) cells into mesenchymal fibroblastic cells, which are implicated in fibrotic disorders of the retina. Herein, the effect of pirfenidone, a novel anti-fibrotic agent, on TGF-β1-mediated fibrogenesis in the human RPE cell line (ARPE)-19 was tested. Methods: The effect of pirfenidone on the TGF-β1-induced phenotype in ARPE-19 cells was measured with immunocytochemistry as the change in F-actin. Fibronectin and collagen production was measured with enzyme-linked immunosorbent assay, and cell migration activity was investigated using a scratch assay. Immunoblot analyses of cofilin, Smad protein (Smad) 2/3, p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and extracellular signal related kinase expression were conducted to elucidate the cell signaling networks that contribute to the anti-fibrotic effect of pirfenidone. Results: Treatment with TGF-β1 induced typical phenotypic changes such as formation of stress fiber running parallel to the long axis of cells, and enhanced migration and production of extracellular matrix components such as collagen type I and fibronectin. This fibroblast-like phenotype induced by TGF-β1 was significantly inhibited by pretreatment with pirfenidone in a dose-dependent manner. Pirfenidone inhibited TGF-β signaling by preventing nuclear accumulation of active Smad2/3 complexes rather than phosphorylation of Smad2/3. Conclusions: These results collectively provide a rational background for future evaluation of pirfenidone as a potential anti-fibrotic agent for treating proliferative vitreoretinopathy and other fibrotic retinal disorders.
- Fulltext
- Appears in Collections:
- Graduate School of Ajou University > Department of Medicine > 4. Theses(Ph.D)
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
- STATISTICS
- Total Visit :3,732,669
- Total Download :1,818
- Today View :10,327
